Beijing Ted Pharmaceuticals was approved for listing on the basis of The Kaoxi tablets

In the international medical community, pain is listed as the fifth largest "vital sign" after "breathing, pulse, blood pressure, body temperature".
2004, the International Pain Society has established the third Monday of October each year as World Pain Aches Day to better spread pain knowledge.
with the aging and hospitalization, the world's major pharmaceutical markets, including China, analgesicals have optimistic market prospects and growth potential.
total sales of analgesy drugs in the U.S. and Europe reached $17.946 billion in 2017, according to public data released by the U.S. Government.
In China, the market for terminal painkillers in public medical institutions is close to 18.4 billion in 2019, while new cancer patients are showing a significant increase in pain sensations, keeping the analgesic end market growing at about 15%, second only to cancer drugs.
relying on Cox-2 highly selective inhibitors, compared with traditional nonsteroidal anti-inflammatory drugs, performance has been improved, the occurrence of adverse reactions decreased by more than 50%, to a certain extent to improve the safety of treatment.
Its original research for Merca East, the commodity named Ankangxin, has been approved in China three adaptive disorders: (1) the treatment of osteoarthritis acute and chronic symptoms and signs;
in 2017, relying on Kaoxi successfully included in the national category B health insurance.
Relying on Kaoxi is currently the only nonsteroidal anti-inflammatory drug with gout-adaptive disease in China, gout prevalence rate in China is 1-3%, the first symptoms are often acute gout arthritis, the current "China Osteoarthritis Guidelines" (1) 2007 edition), The American Rheumatology Society's Gingulation Guidelines (2012 edition), and the China Gingulation Guidelines (2016 edition) have recommended Kaoxi as a treatment drug for related diseases.
。